Evidence map›Paper›PMID 40838586›Full record

ArticleFuture science OA2025

LINC00313 functions as an oncogenic propellant and immunosuppressive marker in lung adenocarcinoma.

Wen Wang, Yanhui Cui, Jianfu Heng, Jingjing Li, Guoli Li

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Future science OA, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Wen WangDepartment of Cardio-Thoracic Surgery, Hunan Provincial People's Hospital (The First-Affiliated Hospital of Hunan Normal University), Changsha, China.
Yanhui CuiCenter of Respiratory Medicine, Xiangya Hospital, Central South University, Changsha, China.
Jianfu HengHunan Cancer Hospital, Affiliated Cancer Hospital of Xiangya School of Medicine, Changsha, China.
Jingjing LiDepartment of Plastic Surgery, Xiangya Hospital, Central South University, Changsha, China.
Guoli LiDepartment of Nephrology and Laboratory of Kidney Disease, Hunan Provincial People's Hospital (The First-Affiliated Hospital of Hunan Normal University), Changsha, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDespite advances in treatments, the prognosis for lung adenocarcinoma (LUAD) remains poor, underscoring the urgent need to identify novel therapeutic strategies. This study was conducted to investigate the potential role of LINC00313 as a biomarker and therapeutic target for LUAD.

methodsDatabases GEPIA2 and GEO were used to analyze LINC00313 expression and prognosis. Analyses of pathways associated with LINC00313, and its relationships with immune infiltration, checkpoint therapy response and drug response were conducted using different bioinformatics tools. siRNA transfection, qRT-PCR, transwell and colony formation assays were performed on LUAD cells (A549).

resultsLINC00313 is significantly upregulated in LUAD, and its expression is associated with high-grade cancer, poor prognosis and metastasis.

conclusionsIn conclusion, LINC00313 holds potential as a valuable biomarker and therapeutic target for the treatment of LUAD. However, further research is warranted to fully elucidate its clinical applications.

Indexed as

biomarkerLINC00313long non-coding RNAsLung adenocarcinomatumor immunology therapy

Identifiers

PMID40838586
PMCPMC12372514

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.